Larotrectinib

Product Description

Larotrectinib is used to treat a certain type of solid tumors in adults and children 1 month of age and older that have spread to other parts of the body or cannot be treated successfully with surgery. This medication is used only if there are no other treatments available and the tumors have worsened after receiving other treatments. Larotrectinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that tells the cancer cells to multiply. This may help slow the growth of tumors. (Sourced from: https://medlineplus.gov/druginfo/meds/a619006.html)

Mechanisms of Action: TRKA Inhibitor,TRKB Inhibitor,TRKC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

Approved Indications: Oncology Solid Tumor Unspecified | Oncology Unspecified

Known Adverse Events: Dizziness | Constipation | Diarrhea

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None